Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03959488 · ClinicalTrials.gov registry record · Phase 2
A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children
A Phase 2 study, sponsored by AstraZeneca.
- Completed
- Registry status
- Phase 2
- Development phase
- 925
- Enrollment target
NCT03959488 is a Phase 2 study that has completed, run by AstraZeneca. The registered enrollment target is 925 participants.
The verdict
NCT03959488, a Phase 2 study, has completed, sponsored by AstraZeneca.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 925 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to palivizumab when administered to preterm infants entering their first RSV season and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV season.
Interventions
- DRUG MEDI8897
- DRUG Palivizumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 925 participants |
| Start Date | 2019-07-30 |
| Est. Completion | 2023-01-20 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03959488
The ClinicalTrials.gov registry entry for NCT03959488 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 925 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AstraZeneca, which has 1,285 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which MEDI8897 is the first listed.
NCT03959488 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03959488 about?
NCT03959488 is a clinical study titled "A Study to Evaluate the Safety of MEDI8897 for the Prevention of Medically Attended Respiratory Syncytial Virus(RSV) Lower Respiratory Track Infection (LRTI) in High-risk Children". The purpose of this study is to evaluate the safety and tolerability of MEDI8897 compared to palivizumab when administered to preterm infants entering their first RSV season and children with chronic lung disease (CLD) and congenital heart disease (CHD) entering their first and second RSV season.
What is the current status of trial NCT03959488?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 925 participants. The study started on 2019-07-30. Estimated completion is 2023-01-20.
What interventions are being tested in trial NCT03959488?
The interventions under investigation include: MEDI8897 (DRUG), Palivizumab (DRUG).
Who is sponsoring clinical trial NCT03959488?
This trial is sponsored by AstraZeneca, which has 1,285 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.